slcompose jto-jto jto-jto jto00308 jto0511-08a$sl

<zkeybdr;disk;js>

<XXjto003080511XX>

<<tt>>TABLE 1.

<mc>Clinicopathologic Features of non-BAC NSCLC Patients (N  = 13,401) with UICC6 T4 and M Descriptors that Undergo Revisions as Proposed by IASLC

 

UICC6 stage IIIB

UICC6 stage IV

T4-“Additional nodules” (%)

T4-“Pleural dissemination” (%)

T4-“Pericardial effusion” (%)

T4-“invasion” (%)

M-“Ipsilateral pulmonary nodules” (%)

M-“Contralateal pulmonary nodules” (%)

M- “distant metastasis” (%)

N

422

1773

320

1607

745

1148

6886

Mean age of diagnosis

67.9

69.6

66.1

66.0

67.4

68.6

65.1

([plusmn]SD)

[plusmn]10.3

[plusmn]11.5

[plusmn]12.3

[plusmn]11.0

[plusmn]10.4

[plusmn]11.3

[plusmn]11.3

Gender

<ems>Male

228 (54.0)

1033 (58.2)

168 (52.5)

952 (59.2)

404 (54.2)

627 (54.6)

3975 (57.7)

<ems>Female

194 (46.0)

740 (41.7)

152 (45.7)

655 (40.8)

341 (45.8)

521 (45.4)

2911 (42.3)

Race

<ems>Caucasian

336 (79.6)

1243 (70.1)

231 (72.2)

1153 (71.8)

537 (72.1)

819 (71.3)

4888 (71.0)

<ems>African-American

31 (7.4)

146 (8.2)

22 (6.9)

159 (9.9)

67 (9.0)

84 (7.3)

630 (9.2)

<ems>Hispanic

26 (6.2)

206 (11.6)

36 (11.3)

138 (8.6)

77 (10.3)

120 (10.5)

703 (10.2)

<ems>Chinese

5 (1.2)

50 (2.8)

5 (1.6)

32 (2.0)

12 (1.6)

31 (2.7)

187 (2.7)

<ems>Non-Chinese Asian

23 (5.5)

123 (6.9)

23 (7.2)

120 (7.5)

51 (6.9)

89 (7.6)

451 (6.6)

<ems>Other

1 (0.2)

5 (0.3)

3 (0.9)

5 (0.3)

1 (0.1)

5 (0.4)

27 (0.4)

Socioeconomic status (SES)

<ems>Quintile 1 (SES1-lowest)

58 (13.7)

339 (19.1)

58 (18.1)

242 (15.1)

120 (16.1)

177 (15.4)

1074 (15.6)

<ems>Quintile 2 (SES2)

83 (19.7)

383 (21.6)

65 (20.3)

318 (19.8)

138 (18.5)

245 (21.3)

1327 (19.3)

<ems>Quintile 3 (SES3)

98 (23.2)

390 (22.0)

82 (25.6)

378 (23.5)

173 (23.2)

254 (22.1)

1505 (21.9)

<ems>Quintile 4 (SES4)

92 (21.8)

360 (20.3)

59 (18.4)

345 (21.5)

156 (20.9)

241 (21.0)

1542 (22.4)

<ems>Quintile 5 (SES5-highest)

91 (21.6)

301 (17.0)

56 (17.5)

324 (20.2)

158 (21.2)

231 (20.1)

1438 (20.9)

Histology

<ems>Adenocarcinoma

211 (50.0)

692 (39.0)

128 (40.0)

528 (32.9)

359 (48.2)

487 (42.4)

3173 (46.1)

<ems>Squamous cell carcinoma

97 (23.0)

503 (28.4)

85 (26.6)

571 (35.5)

196 (26.3)

290 (25.3)

1092 (15.9)

<ems>Large Cell carcinoma

19 (4.5)

111 (6.3)

25 (7.8)

74 (4.6)

28 (3.8)

64 (5.6)

440 (6.4)

<ems>Undifferentiated carcinoma

95 (22.5)

467 (26.3)

82 (25.6)

434 (27.0)

162 (21.7)

307 (26.7)

2181 (31.7)

Histologic grade

<ems>Well-differentiated

29 (6.9)

49 (2.8)

11 (3.4)

37 (2.3)

37 (5.0)

48 (4.2)

115 (1.7)

<ems>Moderately-differentiated

92 (21.8)

254 (14.3)

32 (10.0)

264 (16.4)

146 (19.6)

184 (16.0)

726 (10.5)

<ems>Poorly-differentiated

197 (46.7)

733 (41.3)

128 (40.0)

715 (44.5)

297 (39.9)

405 (35.3)

2436 (35.4)

<ems>Un-differentiated

13 (3.1)

83 (4.7)

21 (6.6)

68 (4.2)

30 (4.0)

44 (3.8)

321 (4.7)

<ems>Unknown

91 (21.6)

654 (36.9)

128 (40.0)

523 (32.5)

235 (31.5)

467 (40.7)

3288 (47.7)

Surgery

<ems>Yes

245 (58.1)

124 (7.0)

13 (4.1)

366 (22.8)

231 (31.0)

89 (7.8)

395 (5.7)

<ems>No

177 (41.9)

1649 (93.0)

307 (95.9)

1241 (77.2)

514 (69.0)

1059 (92.2)

6487 (94.2)

<ems>Unknown

0 (0.0)

0. (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

4 (0.1)

Radiation

<ems>Yes

159 (37.7)

660 (37.2)

122 (38.1)

1081 (67.3)

266 (35.7)

334 (29.1)

3852 (55.9)

<ems>No

263 (62.3)

1113 (62.8)

198 (61.9)

526 (32.7)

479 (64.3)

814 (70.9)

3034 (44.1)

Chemotherapy

<ems>Yes

155 (36.7)

711 (40.1)

155 (48.4)

960 (59.7)

336 (45.1)

549 (47.8)

3141 (45.6)

<ems>No

261 (61.8)

999 (56.3)

154 (48.1)

600 (37.3)

387 (51.9)

562 (49.0)

3524 (51.2)

Unknown

6 (1.4)

63 (3.6)

11 (3.4)

47 (2.9)

22 (3.0)

36 (3.1)

221 (3.2)

<<tabft>></.>

 

<<tt>>TABLE 2.

<mc>Survival Characteristics of non-BAC NSCLC Patients with the Seven Subtypes of UICC6 T4 and M Descriptors that Undergo Revisions as Proposed by IASLC

UICC6 T4 and M descriptors (IASLC proposed changes)

Total

Deaths

1-yr survival estimate (%)

5-yr survival estimate (%)

Median overall survival (mo)

T4-“additional nodules” (IASLC [rarrow] T3)

422

250

64.0

22.6

20

T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb])

1607

1178

47.4

11.5

12

M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4)

745

555

46.2

9.5

11

M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a)

1148

949

31.1

4.3

7

T4-“pleural dissemination” (IASLC [rarrow] M1a)

1773

1557

22.7

3.9

5

T4-“pericardial effusion” (IASLC [rarrow] M1a)

320

282

17.7

3.4

3

M-“distant metastasis” (IASLC [rarrow] M1b)

6886

6252

18.3

1.3

4

<<tabft>></.>

 

<<tt>>TABLE 3.

<mc>Survival Characteristics of non-BAC NSCLC Patients with UICC6 T4 and M Descriptors that Undergo Revisions as Proposed by IASLC Stratified by Individual Histology

UICC6 T4 and M descriptors (IASLC proposed changes)

Total

Deaths

1-yr survival estimate (%)

5-yr survival estimate (%)

Median OS (mo)

Adenocarcinoma (N = 5578)

<ems>T4-“additional nodules” (IASLC [rarrow] T3)

211

117

70.0

25.4

22

<ems>T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb])

528

370

51.6

12.3

13

<ems>M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4)

359

254

54.3

12.6

15

<ems>M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a)

487

390

35.6

6.3

8

<ems>T4-“pleural dissemination” (IASLC [rarrow] M1a)

692

592

24.5

5.0

5

<ems>T4-“pericardial effusion” (IASLC [rarrow] M1a)

128

116

14.4

3.0

3

<ems>M-“distant metastasis” (IASLC [rarrow] M1b)

3173

2829

22.2

1.4

5

Squamous cell carcinoma (N = 2834)

<ems>T4-“additional nodules” (IASLC [rarrow] T3)

97

57

60.0

16.1

17

<ems>T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb])

571

432

45.8

9.7

11

<ems>M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4)

196

156

37.0

6.8

8

<ems>M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a)

290

250

27.6

4.5

7

<ems>T4-“pleural dissemination” (IASLC [rarrow] M1a)

503

435

24.3

3.6

5

<ems>T4-“pericardial effusion” (IASLC [rarrow] M1a)

85

77

15.8

a

4

<ems>M-“distant metastasis” (IASLC [rarrow] M1b)

1092

1024

14.7

1.8

4

Large cell carcinoma (N = 761)

<ems>T4-“additional nodules” (IASLC [rarrow] T3)

19

15

55.7

16.7

12

<ems>T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb])

74

60

42.8

9.3

9

<ems>M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4)

28

19

33.8

16.9

7.5

<ems>M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a)

64

57

28.2

2.4

7

<ems>T4-“pleural dissemination” (IASLC [rarrow] M1a)

111

105

14.5

3.1

3

<ems>T4-“pericardial effusion” (IASLC [rarrow] M1a)

25

20

22.3

a

5

<ems>M-“distant metastasis” (IASLC [rarrow] M1b)

440

414

10.6

1.3

3

Undifferentiated carcinoma (N =  3728)

<ems>T4-“additional nodules” (IASLC [rarrow] T3)

95

61

58.6

15.2

16

<ems>T4-“invasion” (IASLC [rarrow] T4 [lsqb]no change[rsqb])

434

316

45.0

15.3

11

<ems>M-“ipsilateral intra-pulmonary nodules” (IASLC [rarrow] T4)

162

126

40.7

5.7

10

<ems>M-“contralateral intra-pulmonary nodules” (IASLC [rarrow] M1a)

307

252

28.1

2.4

7

<ems>T4-“pleural dissemination” (IASLC [rarrow] M1a)

467

425

20.4

2.6

4

<ems>T4-“pericardial effusion” (IASLC [rarrow] M1a)

82

69

24.3

b

3.5

<ems>M-“distant metastasis” (IASLC [rarrow] M1b)

2181

1985

16.2

1.0

4

<<tabft>>aData suppressed due to no events after 24 mo.

<mc>bData suppressed due to no events after 24 mo.</.>

 

<<tt>>TABLE 4.

<mc>Comparison of Survival Characteristics of the CCR Validation Dataset versus the IASLC SEER Validation Set

 

CCR validation set

IASLC SEER validation set

1-yr survival estimate (%)

Median overall survival (mo)

1-yr survival estimate (%)

Median overall survival (mo)

T4-“additional nodule in same lobe” (IASLC T3)

64.0

20

59a

“Ipsilateral Intra-pulmonary nodules” (IASLC T4)

46.2

11

47a

11a

T4-“invasion” (IASLC T4)

47.4

12

40b

10b

“Contralateral intra-pulmonary nodules” (IASLC M1a)

31.1

7

31b

6b

“Pleural dissemination” (IASLC M1a)

22.7

5

21b

4b

“Distant Metastasis” (IASLC M1b)

18.3

4

15b

3b

<<tabft>>aData from Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage grouping in the forth coming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:694–705.

<mc>bData from Postmus PE, Brambilla E, Chansky K, et al. The IASLC lung cancer staging project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007;2:686–693.</.>

 

<<tt>>TABLE 5.

<mc>Overall Survival of non-BAC NSCLC Patients with “IASLC T4”, Pleural Dissemination and Pericardial Effusion without Distant Metastasis According to Nodal Status

Nodal status

Total

Deaths

1-yr survival estimate (%)

5-yr survival estimate (%)

Median OS (mo)

p

“T4-invasion” (IASLC proposed T4) (N = 1301)

<ems>N0

362

246

54.3

14.8

14

[lt] 0.0001

<ems>N1

126

88

58.8

11.3

16

<ems>N2

707

539

43.6

9.8

11

<ems>N3

106

88

36.5

6.1

9

Malignant pleural dissemination (IASLC proposed M1a) (N = 1773)

<ems>N0

480

398

32.1

6.2

6

[lt] 0.0001

<ems>N1

73

63

31.6

7.4

6

<ems>N2

1050

945

18.3

2.4

4

<ems>N3

170

151

20.0

4.9

5

Malignant pericardial effusion (IASLC proposed M1a) (N = 320)

<ems>N0

33

26

32.5

7.0

5

0.0461

<ems>N1

7

5

28.6

a

7

<ems>N2

206

187

13.8

2.1

3

<ems>N3

74

64

21.8

4.0

5

<<tabft>>aData suppressed due to insufficient events after 10 mo.</.>

 

<<tt>>TABLE 6.

<mc>Pairwise Comparison of Hazards Ratio (HR) of Death between Pericardial Effusion and Other IASLC M Descriptors

Pairwise comparison

HR

95% Confidence Interval

p

Malignant pericardial effusion vs. contralateral intra-pulmonary nodules

1.453

1.271–1.660

[lt] 0.0001

Malignant pericardial effusion vs. malignant pleural dissemination

1.146

1.010–1.302

0.0379

Malignant pericardial effusion vs. distant metastasis (IASLC M1b)

1.032

0.916–1.163

0.6090

<<tabft>></.>

 

<<tt>>TABLE 7.

<mc>Reclassifications of All Patients from the UICC6 Stage Grouping to IASLC Stage Grouping

UICC6 stage grouping (total)

IASLC stage grouping (total)

IA (3000)

IB (2573)

IIA (1509)

IIB (1037)

IIIA (3660)

IIIB (1677)

IVA (3241)a

IVB (6886)a

IA (3000)

3000

IB (3430)

2573

608

249

IIA (338)

338

IIB (1383)

563

607

213

IIIA (2531)

2460

71

IIIB (4122)

181

698

1150

2093

IV (8779)

289

456

1148

6886

<<tabft>></.>

 

<<tt>>TABLE 8.

<mc>Comparison of Overall Survival between UICC6 Staging and IASLC Proposed Staging by Various Stages

UICC6

IASLC

Stage

Total (%)

Deaths

1-yr survival estimate (%)

5-yr survival estimate (%)

Median Overall survival (mo)

Stage

Total (%)

Deaths

1-yr survival estimate (%)

5-yr survival estimate (%)

Median Overall survival (mo)

Stage IA

3000 (12.7%)

889

87.9

52.0

NR

Stage IA

3000 (12.7%)

889

87.9

52.0

NR

Stage IB

3430 (14.5%)

1370

79.4

42.0

45

Stage IB

2573 (10.9%)

968

82.0

44.1

50

Stage IIA

338 (1.4%)

143

84.4

38.2

41

Stage IIA

1509 (6.4%)

718

76.1

32.6

35

Stage IIB

1383 (5.9%)

771

68.5

26.5

25

Stage IIB

1037 (4.4%)

556

68.4

29.3

25

Stage IIIA

2531 (10.7%)

1704

58.4

14.4

15

Stage IIIA

3660 (15.5%)

2424

58.8

15.9

16

Stage IIIB

4122 (17.5%)

3267

36.3

8.7

8

Stage IIIB

1677 (7.1%)

1305

41.4

8.1

10

Stage V

8779 (37.2%)

7756

22.4

2.4

5

Stage IVAa

3241 (13.7%)

2788

25.2

4.1

6

 

 

 

 

 

 

Stage IVBa

6886 (29.2%)

6252

18.3

1.3

4

<<tabft>>aThere is no official stage IVA (M1a) or stage IVB (M1b) as currently proposed by IASLC.

<mc>NR, not reached.</.>

 

<<tt>>TABLE 9.

<mc>Comparison of Median Overall of Advanced Stage non-BAC NSCLC between CCR Validation Set and IASLC SEER Validation Set

 

Median overall survival (mo)

CCR validation set

IASLC SEER validation set

UICC6

IASLC

UICC6

IASLC

Stage IIIA

15

16

14a

14a

Stage IIIB

8

10

8a

9a

Stage IV

5

4a

4a

Stage IVAb

 

6

 

 

Stage IVBb

 

4

 

 

<<tabft>>aData from Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage grouping in the forth coming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:694–705.

<mc>bThere is no official stage IVA (M1a) and stage IVB (M1b) as proposed by IASLC.</.>

 

<<tt>>TABLE 10.

<mc>Pairwise Comparisons of Hazard Ratio of UICC and IASLC Stages

Comparisons

Hazard ratio

p

UICC6

IASLC

UICC6

IASLC

IB vs. IA

1.465 (1.347–1.594)

1.337 (1.221–1.465)

[lt] 0.0001

[lt] 0.0001

IIA vs. IB

0.996 (0.838–1.183)

1.369 (1.243–1.508)

0.9612

[lt] 0.0001

IIB vs. IIA

1.639 (1.371–1.960)

1.267 (1.134–1.415)

[lt] 0.0001

[lt] 0.0001

IIIA vs. IIB

1.481 (1.360–1.613)

1.467 (1.338–1.609)

[lt] 0.0001

[lt] 0.0001

IIIB vs. IIIA

1.623 (1.530–1.721)

1.516 (1.417–1.622)

[lt] 0.0001

[lt] 0.0001

IV vs. IIIB

1.461 (1.403–1.523)

1.770 (1.669–1.876)

[lt] 0.0001

[lt] 0.0001

<<tabft>></.>

 

<<tt>>TABLE 11.

<mc>Comparison of Hazards Ratio of Stage According to UICC6 and IASLC Proposed Staging System Using Cox Proportional Hazards Regression Analysis

UICC6

IASLC

Stage

Hazards ratioa

95% confidence interval

p

Stage

Hazards ratioa

95% confidence interval

p

Stage IA

1.00

 

 

Stage IA

1.00

 

 

Stage IB

1.414

(1.300–1.539)

[lt] 0.0001

Stage IB

1.301

(1.188–1.426)

[lt] 0.0001

Stage IIA

1.607

(1.347–1.918)

[lt] 0.0001

Stage IIA

1.908

(1.729–2.107)

[lt] 0.0001

Stage IIB

2.525

(2.291–2.784)

[lt] 0.0001

Stage IIB

2.360

(2.120–2.626)

[lt] 0.0001

Stage IIIA

2.798

(2.566–3.050)

[lt] 0.0001

Stage IIIA

3.004

(2.767–3.261)

[lt] 0.0001

Stage IIIB

3.686

(3.396–4.002)

[lt] 0.0001

Stage IIIB

3.681

(3.346–4.048)

[lt] 0.0001

Stage IV

5.246

(4.844–5.682)

[lt] 0.0001

Stage IVAb

4.897

(4.493–5.338)

[lt] 0.0001

 

 

 

 

Stage IVBb

6.842

(6.296–7.436)

[lt] 0.0001

<<tabft>>aAdjusted for age, gender, ethnicity, socioeconomic status, histology, histologic grade, surgery, radiation, and chemotherapy.

<mc>bThere is no official stage IVA (M1a) or stage IVB (M1b) as currently proposed by IASLC.</.>

 

<<tt>>SUPPLEMENTAL TABLE 1.

<mc>Cox Multivariate Analysis of the UICC6 Staging System

 

Hazards ratio

95% confidence interval

p

Stage

<ems>Stage IA

1.000

 

 

<ems>Stage IB

1.414

(1.300–1.539)

[lt] 0.0001

<ems>Stage IIA

1.607

(1.347–1.918)

[lt] 0.0001

<ems>Stage IIB

2.525

(2.291–2.784)

[lt] 0.0001

<ems>Stage IIIA

2.798

(2.566–3.050)

[lt] 0.0001

<ems>Stage IIIB

3.686

(3.396–4.002)

[lt] 0.0001

<ems>Stage IV

5.246

(4.844–5.682)

[lt] 0.0001

Age

1.010

(1.008–1.011)

[lt] 0.0001

Gender

<ems>Male

1.000

 

[lt] 0.0001

<ems>Female

0.858

(0.831–0.886)

Ethnicity

<ems>Caucasian

1.000

 

 

<ems>African-American

0.990

(0.933–1.050)

0.7360

<ems>Hispanic

0.954

(0.902–1.008)

0.0956

<ems>Chinese

0.774

(0.698–0.859)

[lt] 0.0001

<ems>Non-Chinese Asian

0.888

(0.831–0.948)

0.0004

<ems>Other

1.032

(0.802–1.328)

0.8040

Histology

<ems>Adenocarcinoma

1.000

 

 

<ems>Squamous cell carcinoma

1.059

(1.019–1.101)

0.0036

<ems>Large cell carcinoma

1.120

(1.040–1.207)

0.0027

<ems>Undifferentiated

1.062

(1.024–1.101)

0.0012

Histologic grade

<ems>Well-differentiated

1.000

 

 

<ems>Moderately-differentiated

1.217

(1.105–1.341)

[lt] 0.0001

<ems>Poorly-differentiated

1.350

(1.230–1.482)

[lt] 0.0001

<ems>Undifferentiated

1.463

(1.296–1.650)

[lt] 0.0001

<ems>Unknown

1.257

(1.143–1.382)

[lt] 0.0001

Socioeconomic status

<ems>Quintile 1 (SES1-lowest)

1.000

 

 

<ems>Quintile 2 (SES2)

0.914

(0.867–0.963)

0.0008

<ems>Quintile 3 (SES3)

0.878

(0.834–0.925)

[lt] 0.0001

<ems>Quintile 4 (SES4)

0.836

(0.793–0.881)

[lt] 0.0001

<ems>Quintile 5 (SES5-highest)

0.809

(0.766–0.854)

[lt] 0.0001

Surgery

<ems>No

1.000

 

[lt] 0.0001

<ems>Yes

0.317

(0.301–0.334)

Radiation

<ems>No

1.000

 

[lt] 0.0001

<ems>Yes

0.883

(0.854–0.914)

Chemotherapy

<ems>No

1.000

 

 

<ems>Yes

0.556

(0.536–0.577)

[lt] 0.0001

<ems>Unknown

0.804

(0.732–0.884)

[lt] 0.0001

<<tabft>></.>

 

<<tt>>SUPPLEMENTAL TABLE 2.

<mc>Cox Multivariate Analysis of the IASLC Proposed Staging System

 

Hazards ratio

95% confidence interval

p

Stage

<ems>Stage IA

1.000

 

 

<ems>Stage IB

1.301

(1.188–1.426)

[lt] 0.0001

<ems>Stage IIA

1.908

(1.729–2.107)

[lt] 0.0001

<ems>Stage IIB

2.360

(2.120–2.626)

[lt] 0.0001

<ems>Stage IIIA

3.004

(2.767–3.261)

[lt] 0.0001

<ems>Stage IIIB

3.681

(3.346–4.048)

[lt] 0.0001

<ems>Stage IVAa

4.897

(4.493–5.338)

[lt] 0.0001

<ems>Stage IVBa

6.842

(6.296–7.436)

[lt] 0.0001

Age

1.011

(1.010–1.013)

[lt] 0.0001

Gender

<ems>Male

1.000

 

[lt] 0.0001

<ems>Female

0.866

(0.839–0.895)

Ethnicity

<ems>Caucasian

1.000

 

 

<ems>African-American

0.992

(0.936–1.052)

0.7940

<ems>Hispanic

0.945

(0.894–1.000)

0.0486

<ems>Chinese

0.762

(0.687–0.845)

[lt] 0.0001

<ems>Non-Chinese Asian

0.891

(0.834–0.952)

0.0006

<ems>Other

1.033

(0.803–1.329)

0.8016

Histology

<ems>Adenocarcinoma

1.000

 

 

<ems>Squamous cell carcinoma

1.086

(1.045–1.129)

[lt] 0.0001

<ems>Large cell carcinoma

1.119

(1.039–1.206)

0.0031

<ems>Undifferentiated

1.063

(1.025–1.102)

0.0010

Histologic grade

<ems>Well-differentiated

1.000

 

 

<ems>Moderately-differentiated

1.174

(1.065–1.294)

0.0012

<ems>Poorly-differentiated

1.289

(1.175–1.415)

[lt] 0.0001

<ems>Undifferentiated

1.375

(1.219–1.552)

[lt] 0.0001

<ems>Unknown

1.183

(1.076–1.301)

0.0005

Socioeconomic status

<ems>Quintile 1 (SES1-lowest)

1.000

 

 

<ems>Quintile 2 (SES2)

0.912

(0.866–0.961)

0.0006

<ems>Quintile 3 (SES3)

0.882

(0.838–0.929)

[lt] 0.0001

<ems>Quintile 4 (SES4)

0.831

(0.788–0.877)

[lt] 0.0001

<ems>Quintile 5 (SES5-highest)

0.808

(0.765–0.853)

[lt] 0.0001

Surgery

<ems>No

1.000

 

[lt] 0.0001

<ems>Yes

0.356

(0.337–0.375)

Radiation

<ems>No

1.000

 

[lt] 0.0001

<ems>Yes

0.869

(0.840–0.899)

Chemotherapy

<ems>No

1.000

 

 

<ems>Yes

0.556

(0.536–0.577)

[lt] 0.0001

<ems>Unknown

0.812

(0.739–0.892)

[lt] 0.0001

<<tabft>>aThere is no official stage IVA (M1a) and stage IVB (M1b) as proposed by IASLC.</.>